Topic

Articles

Craig Coleman, PharmD, Professor at the University of Connecticut, and the Observational Study in Cancer-Associated Thrombosis for Rivaroxaban (OSCAR) study's principal investigator discusses the ins and outs of the study. 

The OSCAR Study: Unlocking the Power of Real-World Evidence in Cancer-Associated Thrombosis

Webcasts

Webinar Date/Time: Mon, Feb 13, 2023 10:00 AM EST


Addressing Operational and Technical Challenges in Home-use Point-of-Care Device Development and Deployment

Webinar Date/Time: Tuesday, December 13, 2022 at 10am ET | 3pm GMT | 4pm CET


Tokenization: Practical Applications in Clinical and Real-World Research

Survey among readers evaluates the trajectory of RWD and how it can be more widely adopted.

Current and Future Use  of Real-World Data 

Addressing sources of tension on differentiating types of data.

Just How ‘Real’ is Real-World Data?

By integrating real-world data more deeply into the process of clinical research, life sciences stakeholders can open up new possibilities for therapeutic development and the evidence-based treatment of hematologic cancers.

Real-World Data Offers Significant Opportunities for Developing New Therapies for Hematologic Cancers

RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals. 

Augmenting Single Arm Oncology and Rare Disease Trials with Real World Evidence

C.K. Wang, MD, senior medical director at COTA Inc., discusses the impact of RWD and RWE in clinical oncology.

The Benefits of RWD & RWE in Oncology Trials

Beth Schurman is Partner at Herspiegel Consulting.

A look at the scope of the agency’s draft framework for evaluating the use of RWE to support new drug approvals and the implications for sponsors.

The Framework for FDA’s  Real-World Evidence Program

With outcomes from “real life” a critical compliment to clinical trial data, the importance of involving an epidemiologist at study inception is explored.